Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Amblyopia
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
Investigators
Jingrong Li
Professor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with amblyopia
- •3-12 years of age
- •Able to tolerate amblyopia treatment
- •Agree to be involved in this study and agree to have a follow up visit every 3 months.
Exclusion Criteria
- •Have previous treatment history before
- •Have pathological ocular anomalies known to cause reduced visual acuity
- •Have previous psychiatric, visual or neurological disorders
- •Have eccentric fixation and/or abnormal retinal correspondence
- •Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
Outcomes
Primary Outcomes
Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics
Time Frame: 2 years after including into this clinical trial
Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.